cjc without dac ipamorelin CJC-1295 (NO DAC) + – Research Peptide CJC-1295 No DAC & Ipamorelin

Overall, in the adjusted analysis (Table 1), the risks of MACE (HR, 0.87), HF (HR, 0.67), and cerebrovascular disease (HR, 0.70) were significantly lower for BS than new users of GLP-1RA

Disclosure of interest: All authors: Nothing to disclose E-Posters - DIAGNOSIS / ETIOLOGY 04.00 - DIAGNOSIS / ETIOLOGY - 04.01 - DIAGNOSIS/INVESTIGATION OF STROKE ETIOLOGY P2354 - ESOC25-772 UTILITY OF PRO-ADRENOMEDULLIN DETERMINATION IN THE STROKE CODE: PRESTO STUDY Cristina Sanabria Gago 1 , Raquel Berbegal Serralta 1 , Jaime Alonso 1 , Vanesa Escribano 2 , Beln Colino Galian 2 , Elena Salgado Barbado 2 , Mnica Sobrado Sanz 3 , Carmen Ramos 1 , Alvaro Ximnez-Carrillo 1 , Elisa de la Fuente Sanz 1 , Alicia Gonzalez-Martinez 1 , Carmen Snchez-Rodrguez 1 , Alba Somovilla 1 , Jose Vivancos 1 , Santiago Trillo Senin 1 1 Neurology Department

Delay in Conventional Treatment: Relying solely on Gerson Therapy may lead to a delay or refusal of conventional, evidence-based cancer treatments, potentially worsening prognosis

It selectively modulates different mechanisms, creating a complex, non-linear, and highly context-dependent benefitrisk profile

Amino Acids 2012 , 736837